Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan
Orphan DrugLicense out/inPhase 2Clinical Result
Preview
Source: Pharmaceutical Technology
Nippon will hold exclusive rights to develop and commercialise Vicore’s C21 in Japan, as per the agreement. Image Credit: FocusStocker / Shutterstock.
Swedish biotech Vicore Pharma has entered an exclusive licensing agreement for the Japanese rights for its idiopathic pulmonary fibrosis (IPF) therapy C21 with Nippon Shinyaku.
Vicore will receive a $10m upfront payment and will be in line to receive up to $275m in development and commercial milestone-based payments. The company will also be placed to get tiered royalties that extend into “the low 20s” based on annual net sales of C21 in Japan, as per a 9 February press release.
Nippon will also contribute financially to the Japanese trial sites and patients in the global late-stage development of C21.
Following the news, Vicore’s stock was up over 18% in trading today. The company’s market cap stands at Skr1.7bn ($162m).
See Also:Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy
Preview
Source: Pharmaceutical Technology
Boehringer and CBmed partner to develop cancer therapies
Preview
Source: Pharmaceutical Technology
C21 is an angiotensin II type 2 receptor agonistangiotensin II type 2 receptor agonist (ATRAG) that activates the protective arm of the renin-angiotensin system (RAS). It has been granted orphan drug designation by both the US Food and Drug Administration and the European Medicines Agency for the treatment of IPF.
The therapy is being evaluated in the Phase IIa AIR trial (NCT04533022). Although the study was disrupted due to the Russia-Ukraine war, it managed to enrol 60 participants. In May 2023, 19 participants completed 36 weeks of treatment, with the therapy demonstrating stabilisation of lung capacity and increased forced expiratory volume at six weeks. Vicore plans to start a global, double-blind, placebo-controlled, 52-week Phase IIb ASPIRE trial in H1 2024.
C21 is also being developed as a treatment for multiple indications including recovery from Covid-19, and endothelial dysfunction in type 2 diabetics. The Phase II ATTRACT trial (NCT04880642) evaluated C21 in hospitalised Covid-19 patients with signs of an acute respiratory infection but not needing mechanical ventilation. The results showed that C21 reduced the risk of needing oxygen by 40% at the end of treatment.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.